Advertisement
U.S. markets close in 2 hours 34 minutes
  • S&P 500

    5,250.35
    +1.86 (+0.04%)
     
  • Dow 30

    39,761.09
    +1.01 (+0.00%)
     
  • Nasdaq

    16,372.59
    -26.94 (-0.16%)
     
  • Russell 2000

    2,127.29
    +12.94 (+0.61%)
     
  • Crude Oil

    82.80
    +1.45 (+1.78%)
     
  • Gold

    2,240.20
    +27.50 (+1.24%)
     
  • Silver

    24.93
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.2000
    +0.0040 (+0.10%)
     
  • GBP/USD

    1.2627
    -0.0011 (-0.09%)
     
  • USD/JPY

    151.3580
    +0.1120 (+0.07%)
     
  • Bitcoin USD

    70,590.77
    +1,391.86 (+2.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Medtronic Micra TPS Pacemaker Meets Initial Safety Levels - Analyst Blog

Medtronic plc’s MDT Micra Transcatheter Pacing System (TPS), which received the European CE Mark a couple of months back, recently met the initial safety and performance measures in its global clinical trial. The study results were announced at a late-breaking clinical trials session in Milan.

Medtronic’s Micra TPS is a single-chamber pacemaker intended for use in patients suffering from symptomatic bradycardia and atrial fibrillation. With a size less than one tenth of that of conventional pacemakers, Micra TPS is the smallest pacemaker to date and can be delivered directly into one’s heart, through minimally invasive procedures.

The latest released data demonstrates successful implantation of Micra TPS in all of the first 140 patients with varied profiles of age, weight and residence at 23 sites across Asia-Pacific, Europe and the U.S. High-risk patients with lung disease such as COPD (chronic obstructive pulmonary disease) and pulmonary hypertension were also considered in this set.

After 1.9 months of observation, six adverse yet manageable events were recorded. Only 1.4% (two patients) required prolonged hospitalization post-implant. This is in line with rates observed in conventional pacemaker studies.

Moreover, no infections or dislodgments were observed; neither was there any untoward event that required surgical re-operation or proved to be fatal. Further, there were zero unanticipated serious adverse device events.

According to Medtronic, this initial trial outcome is quite promising and reflects Micra TPS’ competence vis-à-vis conventional pacemakers. If the company can maintain this strong safety and performance profile with more patients over the long term, this transcatheter pacing therapy device will prove itself highly resourceful in boosting Medtronic’s revenues in this niche, worldwide.

Notably, in the U.S., Micra TPS is still under investigation and management expects to receive approval for commercial use herein in fiscal 2017. We believe the initial trial results will add momentum to this approval process.

Zacks Rank

Currently, the stock carries a Zacks Rank #3 (Hold). Some better-ranked medical products stocks include Bio-Rad Laboratories, Inc. BIO, Hospira Inc. HSP and INSYS Therapeutics, Inc. INSY. All the three stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
MEDTRONIC (MDT): Free Stock Analysis Report
 
HOSPIRA INC (HSP): Free Stock Analysis Report
 
BIO-RAD LABS -A (BIO): Free Stock Analysis Report
 
INSYS THERAP (INSY): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement